Skip to main content
. Author manuscript; available in PMC: 2016 Dec 1.
Published in final edited form as: Hypertension. 2015 Oct 12;66(6):1260–1266. doi: 10.1161/HYPERTENSIONAHA.115.06257

Figure 3. Effective Renal Plasma Flow (eRPF).

Figure 3

a) Male control and growth-restricted (IUGR) rats. b) Female control and growth-restricted rats. eRPF was measured at 16 weeks of age in chronically instrumented, conscious animals pretreated with the angiotensin convertor enzyme inhibitor, enalapril (250mg/L for 1 week). Renal function was measured at baseline during an acute infusion of ANG II (100 ng/kg/min) for 30 min, and during a 30 minute infusion of ANG II plus the ETA receptor antagonist, ABT-627 (10 ng/kg/min for 30min). Values were allowed to return to baseline between acute treatments. *P<0.05 versus baseline control. †P<0.05 versus baseline IUGR. ‡ P< 0.05 vs. ANG II control. # P<0.05 vs. Ang II IUGR. § P< 0.05 vs. ANG+ABT II control. Data values represent mean±SEM.